CCR4 as a Therapeutic Target for Cancer Immunotherapy

CCR4 is a chemokine receptor mainly expressed by T cells. It is the receptor for two CC chemokine ligands, CCL17 and CCL22. Originally, the expression of CCR4 was described as highly selective for helper T type 2 (Th2) cells. Later, its expression was extended to other T cell subsets such as regulat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Osamu Yoshie
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	chemokine chemokine receptor CCR4 T cell subset HTLV-1 ATLL Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/97b407ee681944ee986b13dae52be6d5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:97b407ee681944ee986b13dae52be6d5
record_format	dspace
spelling	oai:doaj.org-article:97b407ee681944ee986b13dae52be6d52021-11-11T15:34:17ZCCR4 as a Therapeutic Target for Cancer Immunotherapy10.3390/cancers132155422072-6694https://doaj.org/article/97b407ee681944ee986b13dae52be6d52021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5542https://doaj.org/toc/2072-6694CCR4 is a chemokine receptor mainly expressed by T cells. It is the receptor for two CC chemokine ligands, CCL17 and CCL22. Originally, the expression of CCR4 was described as highly selective for helper T type 2 (Th2) cells. Later, its expression was extended to other T cell subsets such as regulatory T (Treg) cells and Th17 cells. CCR4 has long been regarded as a potential therapeutic target for allergic diseases such as atopic dermatitis and bronchial asthma. Furthermore, the findings showing that CCR4 is strongly expressed by T cell malignancies such as adult T cell leukemia/lymphoma (ATLL) and cutaneous T cell lymphomas (CTCLs) have led to the development and clinical application of the fully humanized and glyco-engineered monoclonal anti-CCR4 Mogamulizumab in refractory/relapsed ATLL and CTCLs with remarkable successes. However, Mogamulizumab often induces severe adverse events in the skin possibly because of its efficient depletion of Treg cells. In particular, treatment with Mogamulizumab prior to allogenic hematopoietic stem cell transplantation (allo-HSCT), the only curative option of these T cell malignancies, often leads to severe glucocorticoid-refractory graft-versus-host diseases. The efficient depletion of Treg cells by Mogamulizumab has also led to its clinical trials in advanced solid tumors singly or in combination with immune checkpoint inhibitors. The main focus of this review is CCR4; its expression on normal and malignant T cells and its significance as a therapeutic target in cancer immunotherapy.Osamu YoshieMDPI AGarticlechemokinechemokine receptorCCR4T cell subsetHTLV-1ATLLNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5542, p 5542 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chemokine chemokine receptor CCR4 T cell subset HTLV-1 ATLL Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	chemokine chemokine receptor CCR4 T cell subset HTLV-1 ATLL Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Osamu Yoshie CCR4 as a Therapeutic Target for Cancer Immunotherapy
description	CCR4 is a chemokine receptor mainly expressed by T cells. It is the receptor for two CC chemokine ligands, CCL17 and CCL22. Originally, the expression of CCR4 was described as highly selective for helper T type 2 (Th2) cells. Later, its expression was extended to other T cell subsets such as regulatory T (Treg) cells and Th17 cells. CCR4 has long been regarded as a potential therapeutic target for allergic diseases such as atopic dermatitis and bronchial asthma. Furthermore, the findings showing that CCR4 is strongly expressed by T cell malignancies such as adult T cell leukemia/lymphoma (ATLL) and cutaneous T cell lymphomas (CTCLs) have led to the development and clinical application of the fully humanized and glyco-engineered monoclonal anti-CCR4 Mogamulizumab in refractory/relapsed ATLL and CTCLs with remarkable successes. However, Mogamulizumab often induces severe adverse events in the skin possibly because of its efficient depletion of Treg cells. In particular, treatment with Mogamulizumab prior to allogenic hematopoietic stem cell transplantation (allo-HSCT), the only curative option of these T cell malignancies, often leads to severe glucocorticoid-refractory graft-versus-host diseases. The efficient depletion of Treg cells by Mogamulizumab has also led to its clinical trials in advanced solid tumors singly or in combination with immune checkpoint inhibitors. The main focus of this review is CCR4; its expression on normal and malignant T cells and its significance as a therapeutic target in cancer immunotherapy.
format	article
author	Osamu Yoshie
author_facet	Osamu Yoshie
author_sort	Osamu Yoshie
title	CCR4 as a Therapeutic Target for Cancer Immunotherapy
title_short	CCR4 as a Therapeutic Target for Cancer Immunotherapy
title_full	CCR4 as a Therapeutic Target for Cancer Immunotherapy
title_fullStr	CCR4 as a Therapeutic Target for Cancer Immunotherapy
title_full_unstemmed	CCR4 as a Therapeutic Target for Cancer Immunotherapy
title_sort	ccr4 as a therapeutic target for cancer immunotherapy
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/97b407ee681944ee986b13dae52be6d5
work_keys_str_mv	AT osamuyoshie ccr4asatherapeutictargetforcancerimmunotherapy
_version_	1718435196843327488

CCR4 as a Therapeutic Target for Cancer Immunotherapy

Ejemplares similares